BACKGROUND: Hepsin (HPN) is one of the most consistently overexpressed genes in prostate cancer and there is some evidence supporting an association between HPN gene variants and prostate cancer risk. We report results from a population-based case-control genetic association study for six tagging single nucleotide polymorphisms (tagSNPs) in the HPN gene. METHODS: Prostate cancer risk was estimated using adjusted unconditional logistic regression in 1,401 incident prostate cancer cases diagnosed in 1993 through 1996 or 2002 through 2005 and 1,351 age-matched controls. Risks of disease recurrence/progression and prostate cancer-specific mortality were estimated using Cox proportional hazards (PH) regression in 437 cases with long-term follow-up. RESULTS: There were 135 recurrence/progression events and 57 cases who died of prostate cancer. Contrary to some earlier studies, we found no evidence of altered risk of developing prostate cancer overall or when clinical measures of tumor aggressiveness were considered for any of the tagSNPs, assessed either individually or by haplotypes. There was no evidence of altered risks of tumor recurrence/progression or prostate cancer death associated with variants in the HPN gene. CONCLUSIONS: Germline genetic variation of HPN does not seem to contribute to risk of prostate cancer or prognosis.
BACKGROUND:Hepsin (HPN) is one of the most consistently overexpressed genes in prostate cancer and there is some evidence supporting an association between HPN gene variants and prostate cancer risk. We report results from a population-based case-control genetic association study for six tagging single nucleotide polymorphisms (tagSNPs) in the HPN gene. METHODS:Prostate cancer risk was estimated using adjusted unconditional logistic regression in 1,401 incident prostate cancer cases diagnosed in 1993 through 1996 or 2002 through 2005 and 1,351 age-matched controls. Risks of disease recurrence/progression and prostate cancer-specific mortality were estimated using Cox proportional hazards (PH) regression in 437 cases with long-term follow-up. RESULTS: There were 135 recurrence/progression events and 57 cases who died of prostate cancer. Contrary to some earlier studies, we found no evidence of altered risk of developing prostate cancer overall or when clinical measures of tumor aggressiveness were considered for any of the tagSNPs, assessed either individually or by haplotypes. There was no evidence of altered risks of tumor recurrence/progression or prostate cancer death associated with variants in the HPN gene. CONCLUSIONS: Germline genetic variation of HPN does not seem to contribute to risk of prostate cancer or prognosis.
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: J A Magee; T Araki; S Patil; T Ehrig; L True; P A Humphrey; W J Catalona; M A Watson; J Milbrandt Journal: Cancer Res Date: 2001-08-01 Impact factor: 12.701
Authors: S M Dhanasekaran; T R Barrette; D Ghosh; R Shah; S Varambally; K Kurachi; K J Pienta; M A Rubin; A M Chinnaiyan Journal: Nature Date: 2001-08-23 Impact factor: 49.962
Authors: Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Carsten Stephan; George M Yousef; Andreas Scorilas; Klaus Jung; Monika Jung; Glen Kristiansen; Steffen Hauptmann; Tadaaki Kishi; Terukazu Nakamura; Stefan A Loening; Eleftherios P Diamandis Journal: J Urol Date: 2004-01 Impact factor: 7.450
Authors: John S Witte; Brian K Suarez; Bonnie Thiel; Jennifer Lin; Adong Yu; Tarit K Banerjee; James K Burmester; Graham Casey; William J Catalona Journal: Prostate Date: 2003-12-01 Impact factor: 4.104
Authors: Sarah K Holt; Erika M Kwon; Joseph S Koopmeiners; Daniel W Lin; Ziding Feng; Elaine A Ostrander; Ulrike Peters; Janet L Stanford Journal: Prostate Date: 2010-09-15 Impact factor: 4.104
Authors: Kaisa Luostari; Jaana M Hartikainen; Maria Tengström; Jorma J Palvimo; Vesa Kataja; Arto Mannermaa; Veli-Matti Kosma Journal: PLoS One Date: 2014-07-16 Impact factor: 3.240
Authors: Malte Krönig; Max Walter; Vanessa Drendel; Martin Werner; Cordula A Jilg; Andreas S Richter; Rolf Backofen; David McGarry; Marie Follo; Wolfgang Schultze-Seemann; Roland Schüle Journal: Oncotarget Date: 2015-01-20
Authors: H Ross-Adams; A D Lamb; M J Dunning; S Halim; J Lindberg; C M Massie; L A Egevad; R Russell; A Ramos-Montoya; S L Vowler; N L Sharma; J Kay; H Whitaker; J Clark; R Hurst; V J Gnanapragasam; N C Shah; A Y Warren; C S Cooper; A G Lynch; R Stark; I G Mills; H Grönberg; D E Neal Journal: EBioMedicine Date: 2015-07-29 Impact factor: 8.143